Breast Cancer
Feature
Long-term breast cancer studies yield encouraging data for recurrence, survival
News
ASCO updates postmastectomy radiotherapy guideline
Key clinical point: The ASCO clinical practice guideline on postmastectomy radiotherapy has been updated to help clinicians decide which patients...
News
New anticancer drugs linked to increased costs, life expectancy
News
Large retrospective study challenges updated ASCO-CAP HER2 categorizations
Key clinical point: Clinical trial data support the original ASCO-CAP categories for HER2 status, not the updated categories from the most recent...
News
Breast density is key to appropriate screening intervals
Key clinical point: Breast density is a key factor in determining appropriate screening intervals for mammography after age 50. Major finding:...
News
Guideline recommends 2-mm negative margins for DCIS
Experts from three oncology societies provide evidence-based recommendations for treating patients with ductal carcinoma in situ.
News
Estrogen receptor mutations linked with worse outcomes in MBC
Key clinical point: Estrogen receptor mutations in aromatase inhibitor–treated ER-positive metastatic breast cancer patients are common and are...
News
ESR1 mutations found prognostic but not predictive in metastatic breast cancer
Key clinical point: An ESR1 mutation in circulating DNA after progression on endocrine therapy was a marker for poor prognosis but did not predict...
News
Young age, tumor subtype linked in breast cancer survival
Key clinical point: Younger age at diagnosis of breast cancer predicts poor survival only with certain molecular subtypes of tumor. Major finding...
News
Clinical value of costly ER/PR testing of ductal carcinoma biopsies questioned
Limiting hormone receptor testing of diagnostic core biopsies with DCIS could save up to $35 million in associated health care costs every year in...
News
Anthracycline benefit for high-risk breast cancer confirmed in joint analysis
Key clinical point: Anthracyclines continue to have a role in the treatment of high-risk, HER2-negative breast cancer.